Assessing Pro Medicus’s Valuation After Director Buying And Upcoming Dividend Attract Attention

Simply Wall St.

20 hours ago

Pro Medicus (ASX:PME) is back in focus after co founders and directors bought A$3.4 million of shares on market, with investors also eyeing the upcoming interim dividend payment on March 20. See our ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2617562035"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2617562035\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2617562035?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/9551730-choice1-main-header/1585186828574","is_english":true,"pubTime":"2026-03-05 03:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2617562035","market":"us","top_or_hot":-1,"title":"Assessing Pro Medicus’s Valuation After Director Buying And Upcoming Dividend Attract Attention","media":"Simply Wall St.","content":"<div>\n<p>Pro Medicus (ASX:PME) is back in focus after co founders and directors bought A$3.4 million of shares on market, with investors also eyeing the upcoming interim dividend payment on March 20. See our ...</p>\n\n<a href=\"https://simplywall.st/stocks/au/healthcare/asx-pme/pro-medicus-shares/news/assessing-pro-medicuss-valuation-after-director-buying-and-u\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing Pro Medicus’s Valuation After Director Buying And Upcoming Dividend Attract Attention</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing Pro Medicus’s Valuation After Director Buying And Upcoming Dividend Attract Attention\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-05 03:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/au/healthcare/asx-pme/pro-medicus-shares/news/assessing-pro-medicuss-valuation-after-director-buying-and-u><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pro Medicus (ASX:PME) is back in focus after co founders and directors bought A$3.4 million of shares on market, with investors also eyeing the upcoming interim dividend payment on March 20. See our ...</p>\n\n<a href=\"https://simplywall.st/stocks/au/healthcare/asx-pme/pro-medicus-shares/news/assessing-pro-medicuss-valuation-after-director-buying-and-u\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7094","symbol_name":"医疗保健技术","start_time":0,"source_url":"https://simplywall.st/stocks/au/healthcare/asx-pme/pro-medicus-shares/news/assessing-pro-medicuss-valuation-after-director-buying-and-u","article_id":"2617562035","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/9551730-choice1-main-header/1585186828574"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/healthcare/asx-pme/pro-medicus-shares/news/assessing-pro-medicuss-valuation-after-director-buying-and-u","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2617562035","pubTimestamp":1772652356,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Pro Medicus (ASX:PME) is back in focus after co founders and directors bought A$3.4 million of shares on market, with investors also eyeing the upcoming interim dividend payment on March 20.\nSee our latest analysis for Pro Medicus.\nDespite the director buying and upcoming dividend, Pro Medicus shares have experienced a sharp reset, with a 30 day share price return of a 34.8% decline and a 1 year total shareholder return of a 55.6% decline, contrasting with still positive 3 and 5 year total...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7094":"医疗保健技术","PME.AU":"PRO MEDICUS LTD"},"translate_title":"董事收购和即将派发股息后评估Pro Medicus的估值引起关注","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PME.AU":1},"content_text":"Pro Medicus (ASX:PME) is back in focus after co founders and directors bought A$3.4 million of shares on market, with investors also eyeing the upcoming interim dividend payment on March 20. See our latest analysis for Pro Medicus. Despite the director buying and upcoming dividend, Pro Medicus shares have experienced a sharp reset, with a 30 day share price return of a 34.8% decline and a 1 year total shareholder return of a 55.6% decline, contrasting with still positive 3 and 5 year total shareholder returns. This suggests longer term holders have seen gains even as recent momentum has been weak. If this recent pullback has you reassessing growth names in healthcare and imaging, it could be a good moment to scan 10 healthcare AI stocks as potential alternatives or complements on your watchlist. With shares resetting hard despite longer term gains and with revenue and net income growth still positive, the key question now is simple: is Pro Medicus trading at a discount, or is the market already pricing in its future growth? AdvertisementMost Popular Narrative: 41% Undervalued According to the most followed narrative, Pro Medicus has a fair value of A$196.78 per share versus the last close at A$116.19, which frames the current reset in a very different light.  At $120, the stock offers an asymmetric setup: you are not buying a distressed company, you are buying a best-in-class franchise that has temporarily disappointed quarterly expectations in a business where revenue is inherently lumpy. The contract backlog, the renewal rate, the margin profile, and the expanding addressable market have not changed. The price has.  Read the complete narrative. Curious what underpins that valuation gap? The narrative leans heavily on compounding revenue, thick margins and a premium profit multiple that assumes continued contract momentum. The exact mix of those inputs might surprise you. Result: Fair Value of A$196.78 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this bullish narrative could unravel if hospital imaging volumes soften, or if AI tools reduce radiologists’ reliance on Pro Medicus’ software faster than expected. Find out about the key risks to this Pro Medicus narrative. Another Lens on Valuation That 41% undervaluation call sits awkwardly next to Pro Medicus trading on a 50.9x P/E, compared with a 29.2x peer average, a 31.2x global industry average, and a fair ratio of 32x. If sentiment cools, the share price could potentially drift toward that lower multiple. See what the numbers say about this price — find out in our valuation breakdown. ASX:PME P/E Ratio as at Mar 2026Next Steps If this mix of optimism and concern feels finely balanced, it may be worth acting quickly to review the full picture for yourself, including 2 key rewards and 1 important warning sign. Looking for more investment ideas? If Pro Medicus has sharpened your thinking, do not stop here. Broaden your watchlist with a few focused screens that surface very different types of opportunities.  Target potential mispricings by scanning our 7 high quality undervalued stocks that pair solid fundamentals with prices the market may be overlooking. Strengthen your income stream by reviewing 7 dividend fortresses that aim for yields of 5% or more with an eye on stability. Prioritise resilience by checking 7 resilient stocks with low risk scores designed to spotlight companies with lower risk scores and sturdier profiles.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}